Skip to main content

Table 2 Summary of studies in complicated intra-abdominal infection (cIAI)

From: Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

   CCR-TOCa     
Index Reference Agent A Agent B Description Quality high (H) or medium (M) Comparative outcome (A vs B) Year
A [27] Doripenem mITT 85.9 % (140/163) Meropenem mITT 85.3 % (133/156) R, DB, P3 H Noninferior 2008
B [28] Tigecycline 86.1 % (441/512) Imipenem-cilastatin 86.2 % (442/513) Pooled analysis of two phase 3 trials. H Noninferior 2005
C [29] Tigecycline 92.4 % (219/237) Imipenem-cilastatin 88.8 % (198/223) Subanalysis of the European data from Study B H - 2008
D [30] Tigecycline 80.6 % (199/247) Imipenem-cilastatin 82.4 % (210/255) R, DB, P3 H - 2005
E [31] Tigecycline mITT 86.5 % (45/52) Imipenem-cilastatin mITT 97.9 % (47/48) R, OL, P3 M - 2010
F [32] Tigecycline 81.8 % (162/198) Ceftriaxone-metronidazole 79.4 % (150/189) R, OL M Noninferior 2012
G [14] Ertapenem 79.3 % (245/311) Piperacillin-tazobactam 76.2 % (232/304) R, DB, P3 H Equivalent 2003
H [33] Piperacillin-tazobactam “Clinical success” 97.3 % (108/111) Imipenem-cilastatin “Clinical success” 97.1 % (100/103) R M/H - 2004
I [34] Piperacillin-tazobactam followed by amoxicillin clavulanate For HAI: 55 % (17/31) Moxifloxacin For HAI: 82 % (22/27) R, DB, P3 M   2006
J [35] Ceftolozane-tazobactam + metronidazole 91.4 % (64/70) Meropenem 94.3 % (33/35) R, DB, P2 M - 2014
K [36] Ceftolozane-tazobactam 83.8 % (399/476) Meropenem 85.8 % (424/494) R, DB, P3 H Noninferior  
L [37] Ceftazidime-avibactam + metronidazole 91.2 % (62/68) Meropenem 93.4 % (71/76) R, P2 M - 2013
  1. CCR-TOC clinical cure rate at the test-of-cure endpoint, DB double-blind, HAI hospital-acquired infection, MIC minimum inhibitory concentration, mITT microbiologically evaluable intent-to-treat population, OL open-label, P2 phase 2, P3 phase 3, R randomized.
  2. aUnless otherwise noted.